외래환자 암 치료용 주입 시장 기회, 성장 촉진요인, 산업 동향 분석, 예측(2024-2032년)

The Global Outpatient Oncology Infusion Market was valued at USD 2.4 billion in 2023. Projections indicate a growth trajectory, with an expected CAGR of 10.6% from 2024 to 2032. This robust market expansion is fueled by technological strides in infusion pumps, a rising cancer prevalence, and broader healthcare policies and insurance coverage. Such dynamics bolster the transition to outpatient treatments, lauded for their cost-effectiveness and efficiency. Cancer remains a pressing global public health challenge, underscored by rising cases and mortality rates. For instance, the American Cancer Society reported approximately 608,570 cancer-related deaths in the U.S. in 2021. Breast cancer topped the list with 284,200 new cases, followed by prostate and lung cancers.

This significant cancer burden amplifies the demand for infusion therapies and drug infusion systems, propelling the market growth. Several pivotal trends are shaping the market trajectory. These encompass a growing geriatric demographic and a pronounced shift towards outpatient facilities, driven by comfort, cost-effectiveness, and technological innovations. Moreover, evolving healthcare policies and rising survival rates are poised to bolster the market during the forecast period.

The overall industry is divided into product, application, therapy, mode, and region. The market categorizes products into infusion pumps, intravenous sets, IV cannulas, and needleless connectors. Leading the pack, the infusion pumps segment raked in USD 1.2 billion in revenue in 2023. Their rising adoption in outpatient cancer therapies is attributed to precise drug delivery, the capability to handle intricate chemotherapy regimens, and enhanced patient outcomes. Infusion pumps ensure continuous, controlled delivery of chemotherapeutic agents, minimizing dosage errors and amplifying treatment efficacy.

Applications in the outpatient oncology infusion market span lung, liver, breast, prostate cancers, and others. In 2023, breast cancer led the charge with a 20.5% market share. This dominance stems from its global prevalence, a spectrum of advanced treatment avenues, a tilt towards outpatient care, and robust patient support mechanisms. Notably, Global Cancer Statistics 2022 highlighted 2.3 million new female breast cancer cases in 2022.North America, with a 2023 revenue of USD 1 billion, is set to grow at a CAGR of 10% from 2024 to 2032. The region's leadership is driven by a surge in cancer prevalence, underscoring the need for efficient treatment avenues like outpatient oncology infusions.A heightened cancer awareness, emphasizing early diagnosis, further cements North America's position. Public health initiatives, screening advancements, and diagnostic tech progress have further played roles in facilitating timely cancer interventions and treatments.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Recent technological advancements in infusion pumps
    • 3.2.1.2 Rising prevalence of cancer across the globe
    • 3.2.1.3 Surging government initiatives for cancer awareness
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High costs of cancer therapies
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technology landscape
• 3.6 Reimbursement scenario
• 3.7 Porter's analysis
• 3.8 PESTEL analysis
• 3.9 Future market trends
• 3.10 Gap analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Infusion pumps
• 5.3 Intravenous sets
• 5.4 IV cannulas
• 5.5 Needleless connectors

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Lung cancer
• 6.3 Liver cancer
• 6.4 Breast cancer
• 6.5 Prostate cancer
• 6.6 Other cancers

Chapter 7 Market Estimates and Forecast, By Therapy, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Chemotherapy
• 7.3 Targeted therapy
• 7.4 Immunotherapy
• 7.5 Hormonal therapy

Chapter 8 Market Estimates and Forecast, By Mode, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Intramuscular (IM)
• 8.3 Intravenous (IV)
• 8.4 Subcutaneous
• 8.5 Other modes

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 B. Braun Melsungen AG
• 10.2 Baxter
• 10.3 Becton, Dickinson, and Company
• 10.4 Fresenius Kabi
• 10.5 ICU Medical, Inc
• 10.6 IRadimed Corporation
• 10.7 Medtronic PLC
• 10.8 Micrel Medical Devices SA
• 10.9 Moog, Inc.
• 10.10 Nipro Corporation
• 10.11 Roche Diagnostics
• 10.12 Smiths Medical
• 10.13 Teleflex, Inc.
• 10.14 Terumo Corporation